Key Stats
- 52-Week Range: $330 to $557
- Current Price: $423
- Street Mean Target: $513
- Street High Target: $635
- TIKR Model Target (Dec. 2030): $770
HCA Healthcare Stock Drops 8% After Flu Season Shortfall Masks a Solid Quarter
HCA Healthcare (HCA) is the largest publicly traded hospital operator in the United States, running roughly 190 hospitals and 2,500 ambulatory sites across 43 high-growth domestic markets, and following its Q1 2026 earnings report on April 24, the stock dropped 8% despite the company beating analyst estimates on both revenue and adjusted EPS.
Revenue came in at $19.11 billion for the quarter, up 4.3% from a year earlier and slightly ahead of the $19.10 billion consensus.
Adjusted EPS rose 10.9% year-over-year to $7.15, a one-cent beat on the $7.14 analyst estimate.
The miss that rattled investors was not in the income statement — it was in volumes: respiratory-related admissions fell 42% versus the prior-year quarter, and respiratory-related emergency room visits dropped 32%, eliminating the seasonal lift HCA normally captures during flu season.
A January winter storm across Texas, Tennessee, North Carolina, and Virginia compounded the pressure, and together the two factors knocked an estimated $180 million off adjusted EBITDA for the quarter.
Chief Financial Officer Mike Marks drew a firm line between weather and business trajectory on the Q1 2026 earnings call, stating: “We view these factors as being temporal and not structural.”
HCA offset a significant portion of the volume drag through Medicaid supplemental payment programs, including the grandfathered approval of Georgia and the reinstatement of the ATLIS program in Texas, generating approximately $200 million in net supplemental benefit versus the $80 million the company had anticipated entering the quarter.
CEO Sam Hazen confirmed that February and March volumes rebounded close to plan, and HCA reaffirmed its full-year 2026 guidance: revenue of $76.5 billion to $80 billion and diluted adjusted EPS of $29.10 to $31.50.
Wall Street’s Take on HCA Stock
The central question after Q1 is whether the volume shortfall was a weather event or an early signal of structural deterioration from the expiration of enhanced Affordable Care Act subsidies, and most of the Street has landed firmly on the former.
HCA guided to a $600 million to $900 million EBITDA headwind from ACA exchange changes in 2026, built around assumptions of a 15% to 20% decline in exchange volume, 15% to 20% of those patients migrating to employer-sponsored insurance, and the remainder moving to uninsured status with reduced utilization. Exchange equivalent adjusted admissions declined approximately 15% in Q1, landing at the low end of that range and within expectations.
Consensus estimates now project full-year 2026 revenue of around $79 billion with EPS Normalized of around $30, before accelerating to around $82 billion in revenue and around $33 in EPS for fiscal 2027, representing high-single-digit earnings growth on a per-share basis even as the company absorbs a major payer mix headwind.
The resiliency program is the underappreciated offset: HCA has identified $400 million in 2026 cost savings spanning revenue integrity, asset optimization, and fixed and variable cost reduction, all supported by AI-enabled revenue cycle tools, supply chain platform HealthTrust, and the Parallon revenue cycle shared services operation.
With 16 analysts rating HCA Healthcare stock a Buy or Strong Buy against 9 Holds and 1 Sell, and a mean Street price target of $554.50 implying around 31% upside from current levels, the analyst community is betting that a normalized operating environment in Q2 through Q4 will close the gap between where the stock trades today and where the fundamentals justify it trading.
What Does the Valuation Model Say?
TIKR’s base case values HCA Healthcare at around $770 per share, anchored to a mid-case revenue CAGR of around 5% from 2025 through 2035 and a net income margin assumption of 8.6%, a level the company has demonstrated it can sustain even in a pressured payer mix environment like Q1.
At $423 per share against a TIKR model target of around $770, the math implies around 82% total return potential over the holding period, and on that basis HCA Healthcare stock is undervalued by a margin that is difficult to explain through ACA headwinds alone.
The argument for HCA in 2026 hinges on one question: are the Q1 volume headwinds the start of a structural decline, or a seasonally distorted quarter that the company’s own exit data has already answered?
Base Case:
- Q2 through Q4 volumes normalize to the 2% to 3% growth range management guided, consistent with February and March trends already running near plan
- The $400 million resiliency program delivers on schedule, with AI-enabled revenue cycle tools, HealthTrust supply chain savings, and Parallon shared services absorbing the bulk of the ACA exchange EBITDA impact
- Florida Medicaid supplemental program, covering October 2024 through September 2025, receives CMS approval and contributes incremental revenue that management has described as potentially significant
- Operating cash flow of $12 billion to $13 billion for the full year funds $5 billion to $5.5 billion in CapEx, continued share repurchases under the $10 billion authorization, and a growing dividend — all without meaningful leverage increase
- EPS Normalized reaches approximately $30 for the full year, supporting re-rating toward the stock’s historical 16x forward earnings multiple; 2027 consensus sits at around $33, extending the per-share growth runway
Downside Risk:
- ACA exchange volume declines accelerate beyond the 15% to 20% range as premium effectuation rates deteriorate faster than modeled, pressuring the high end of the $600 million to $900 million EBITDA headwind range
- Florida Medicaid program approval is delayed beyond 2026, removing a potential upside offset management has flagged as material
- Hospital-based physician costs, which grew 20% in 2024 and 10% in 2025, remain in high single-digit territory in 2026 and beyond, limiting the operating leverage the resiliency program is designed to generate
- Medicaid redetermination slowdown accelerates from the nascent trend seen in Q1, as hesitancy around benefit applications reduces conversion rates and pushes more patients into uninsured status
Is HCA Healthcare stock undervalued?
At 13.69x NTM normalized earnings against a 3-year historical mean of 14.82x, HCA Healthcare stock is trading at a discount to its own average multiple while EPS grows and full-year guidance holds firm.
The $400 million resiliency program, $2 billion in Q1 operating cash flow, and reaffirmed 2026 outlook describe a business in better shape than an 8% post-earnings selloff implies, and on that basis HCA Healthcare stock appears undervalued.
Should You Invest in HCA Healthcare, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up HCA Healthcare, Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track HCA Healthcare, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze HCA stock on TIKR for Free →
